189 related articles for article (PubMed ID: 33909097)
1. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Shapiro GI; Kristeleit RS; Burris HA; LoRusso P; Patel MR; Drew Y; Giordano H; Maloney L; Watkins S; Goble S; Jaw-Tsai S; Xiao JJ
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):107-118. PubMed ID: 29799676
[TBL] [Abstract][Full Text] [Related]
4. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Green ML; Ma SC; Goble S; Giordano H; Maloney L; Simmons AD; Beltman J; Harding TC; Xiao JJ
Cancer Chemother Pharmacol; 2022 May; 89(5):671-682. PubMed ID: 35397664
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Liao M; Beltman J; Giordano H; Harding TC; Maloney L; Simmons AD; Xiao JJ
Clin Pharmacokinet; 2022 Nov; 61(11):1477-1493. PubMed ID: 36107395
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Rolfo C; Isambert N; Italiano A; Molife LR; Schellens JHM; Blay JY; Decaens T; Kristeleit R; Rosmorduc O; Demlova R; Lee MA; Ravaud A; Kopeckova K; Learoyd M; Bannister W; Locker G; de Vos-Geelen J
Br J Clin Pharmacol; 2020 Sep; 86(9):1807-1818. PubMed ID: 32227355
[TBL] [Abstract][Full Text] [Related]
9. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
[TBL] [Abstract][Full Text] [Related]
11. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
[TBL] [Abstract][Full Text] [Related]
12. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Moore DC; Ringley JT; Patel J
J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
[TBL] [Abstract][Full Text] [Related]
13. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
[TBL] [Abstract][Full Text] [Related]
14. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
15. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Lorusso D; Maltese G; Sabatucci I; Cresta S; Matteo C; Ceruti T; D'Incalci M; Zucchetti M; Raspagliesi F; Sonetto C; Sinno V; Ronzulli D; Giolitto S; de Braud F
Target Oncol; 2021 Jan; 16(1):59-68. PubMed ID: 33369704
[TBL] [Abstract][Full Text] [Related]
16. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.
Lorusso D; García-Donas J; Sehouli J; Joly F
Target Oncol; 2020 Jun; 15(3):391-406. PubMed ID: 32495160
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
[TBL] [Abstract][Full Text] [Related]
20. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
